title: [Progress of gene therapy for hemophilia].
abstract: Hemophilia is a hereditary hemorrhagic disease induced by synthesis reducing of clotting factors or functional defect because of genetic mutations, Its treatment methods include traditional replacement therapy and new types of gene therapy. Replacement therapy is to reduce the bleeding complication and prevent the loss of function through the infusion exogenous recombinant coagulation factor, and gene therapy is to import the gene that exogenous code clotting factor into the patients' body by gene transfer technology, and express the treatment level of clotting factors to achieve the purpose of the permanent cure hemophilia. The various factors which affecting effects of the hemophilia's gene therapy include carrier factors, target cell factors, the timing of treatment, immune response caused by carrier. This review summarizes briefly the research progress of the factors affecting the gene therapy for hemophilia.
authors: Department of Examination Medicine, Guiyang Medical College, Guiyang 550004, Guizhou Province, China.
authors: Ling
authors: L
authors: Yan
authors: Department of Examination Medicine, Guiyang Medical College, Guiyang 550004, Guizhou Province, China. E-mail: gyshuxueke@126.com.
authors: Xiao-Jing
authors: XJ
authors: Zeng
mesh_terms: D001779:Blood Coagulation Factors; D015316:Genetic Therapy; D006467:Hemophilia A; D006801:Humans
chemical_list: D001779:Blood Coagulation Factors